Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities

The aberrant c-Met activation has been implicated in a variety of human cancers for its critical role in tumor growth, metastasis and tumor angiogenesis. Thus, c-Met axis presents as an attractive therapeutic target. Notably, most of these c-Met inhibitors currently being evaluated in clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ying, Zhan, Zhengsheng, Jiang, Xifei, Peng, Xia, Shen, Yanyan, Chen, Fang, Ji, Yinchun, Liu, Weiren, Shi, Yinghong, Duan, Wenhu, Ding, Jian, Ai, Jing, Geng, Meiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122374/
https://www.ncbi.nlm.nih.gov/pubmed/27191264
http://dx.doi.org/10.18632/oncotarget.9349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122374/
https://www.ncbi.nlm.nih.gov/pubmed/27191264
http://dx.doi.org/10.18632/oncotarget.9349

Ejemplares similares